- Home
- TVRD vs JOB Comparison
TVRD vs JOB Comparison
Compare TVRD & JOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVRD | JOB |
|---|---|---|
| Founded | 2017 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 23.9M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVRD | JOB |
|---|---|---|
| Price | $1.29 | $0.23 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | 189.8K | ★ 190.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $911,000.00 | ★ $96,504,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 959.30 | N/A |
| 52 Week Low | $0.93 | $0.17 |
| 52 Week High | $43.65 | $0.28 |
Technical Indicators
Market Signals| Indicator | TVRD | JOB |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 46.11 |
| Support Level | N/A | $0.22 |
| Resistance Level | $2.02 | $0.27 |
| Average True Range (ATR) | 0.16 | 0.01 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 35.51 | 32.50 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
About JOB GEE Group Inc.
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.